SCHEMBL960756

SCHEMBL960756

COCCc1cc(C)ccc1S(=O)(=O)O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MEP1B Q16820 2/20 0.36
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 2/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
AMY1A P0DUB6 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
POLB P06746 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773853 0.91 HPGD (0.34) HPGDMEN1KMT2AMEP1BALDH1A1
SCHEMBL2534658 0.91 HPGD (0.34) HPGDMEN1KMT2AMEP1BALDH1A1
SCHEMBL5861868 0.91 HPGD (0.34) HPGDMEN1KMT2AMEP1BALDH1A1
SCHEMBL8686435 0.91 MAPT (0.40) HPGDMEN1KMT2AMEP1BALDH1A1
SCHEMBL1127903 0.89 MAPT (0.40) HPGDMEN1KMT2AMEP1BALDH1A1
SCHEMBL1648239 0.89 GAA (0.36) MEN1KMT2AMEP1BALDH1A1KDM4E
SCHEMBL478439 0.87 TAAR1 (0.36) MEN1KMT2AMEP1BALDH1A1KDM4E
SCHEMBL516227 0.87 TAAR1 (0.36) MEN1KMT2AMEP1BALDH1A1KDM4E
SCHEMBL29488092 0.87 TAAR1 (0.36) MEN1KMT2AMEP1BALDH1A1KDM4E
SCHEMBL29790344 0.87 TAAR1 (0.36) MEN1KMT2AMEP1BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108999-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 CN claimed
CN-115108999-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-09-27 CN claimed
WO-2021017996-A1 PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 暨南大学 2021-02-04 WO claimed
CN-112300082-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2021-02-02 CN claimed
CN-114075221-B Substituted heteroaryl compounds, compositions and uses thereof 广东东阳光药业股份有限公司 2024-08-23 CN disclosed
EP-4399202-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2024-07-17 EP disclosed
CN-115108999-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 CN disclosed
CN-114920704-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 CN disclosed
US-20230339977-A1 SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND APPLICATION THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-10-26 US disclosed
WO-2023072962-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-05-04 WO disclosed
EP-4169904-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-04-26 EP disclosed
CN-115108999-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-09-27 CN disclosed
EP-0200843-A1 Process for the photochemical stabilisation of undyed and dyed polyamide fibrous material and its mixtures CIBA-GEIGY AG (CH) 1986-11-12 EP disclosed
US-4616015-A HYPOTENSIVE AGENT, ANTULCER AGENT, ANTICOAGULANT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-10-07 US disclosed
US-4587342-A 2,4-diamino-(substituted-benzopyran(quinolyl,isoquinoly)methyl)pyrimidines useful as antibacterials SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 1986-05-06 US disclosed
EP-0051879-B1 SUBSTITUTED PYRIMIDINES, THEIR SYNTHESIS AND COMPOSITIONS CONTAINING THEM, THEIR USE IN MEDICINE AND INTERMEDIATES FOR MAKING THEM THE WELLCOME FOUNDATION LIMITED (GB) 1986-02-05 EP disclosed
EP-0122627-A2 Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-24 EP disclosed
EP-0017209-B1 SUBSTITUTED ALKYLAMMONIUM SALTS, THEIR PREPARATION AND USE IN PLANT GROWTH REGULATION BASF Aktiengesellschaft (DE) 1982-12-22 EP disclosed
EP-0051879-A2 Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them THE WELLCOME FOUNDATION LIMITED (GB) 1982-05-19 EP disclosed
EP-0017209-A1 Substituted alkylammonium salts, their preparation and use in plant growth regulation BASF Aktiengesellschaft (DE) 1980-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339977-A1 SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND APPLICATION THEREOF TYK2, JAK1, JAK3 HPGD 3112/4885MEN1 3940/4885KMT2A 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.